Biogen Inc. Common Stock BIIB

Biogen Inc. es una empresa global de biotecnología. La compañía se enfoca en descubrir, desarrollar y ofrecer terapias para personas que viven con enfermedades graves y complejas en todo el mundo. Tiene un portafolio de medicamentos para tratar la esclerosis múltiple (EM), la atrofia muscular espinal (AME) y la enfermedad de Alzheimer. Se centra en avanzar en su cartera en neurología, neuropsiquiatría, inmunología especializada y enfermedades raras. Sus productos comercializados incluyen TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI y FAMPYRA para el tratamiento de la EM; SPINRAZA para el tratamiento de la AME; ADUHELM para el tratamiento de la enfermedad de Alzheimer, y FUMADERM para el tratamiento de la psoriasis en placas severa. También está avanzando en sus programas de etapa intermedia a tardía, incluyendo zuranolone para el trastorno depresivo mayor (TDM) y la depresión posparto (DPP), BIIB080 para la enfermedad de Alzheimer, tofersen para la esclerosis lateral amiotrófica (ELA) y tanto litifilimab como dapirolizumab pegol para ciertas formas de lupus.

• Zacks Investment Research 2 oct

  Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?

  AbbVie received FDA approval for Juvmo, a once-daily oral treatment for Parkinson's disease launching in October 2026. As the first selective D1/D5 dopamine receptor agonist usable as standalone or combination therapy, Juvmo expands AbbVie's PD portfolio alongside Vyalev and Duopa, with the three therapies expected to generate peak sales above $5 billion. The approval validates AbbVie's $8.7 billion Cerevel Therapeutics acquisition and strengthens its neuroscience segment, which grew 22% year-over-year.

  

• The Motley Fool 20 sept

  Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook

  Ionis Pharmaceuticals stock has plummeted over 40% this year due to late-stage clinical trial failures and ongoing losses, yet Wall Street analysts maintain a bullish outlook with an average price target of $83.82. Despite setbacks with pelacarsen and eplontersen programs, the company's strong ASO technology platform, solid $2.1 billion cash position, and recent FDA approval of Zanvastro for Alexander disease provide potential for long-term investors willing to wait several years for profitability.

  

• GlobeNewswire Inc. 17 sept

  Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

  The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

  

• GlobeNewswire Inc. 15 sept

  Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

  The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

  

• GlobeNewswire Inc. 15 sept

  Hummingbird Bioscience Appoints Dr. James Garner as President

  Hummingbird Bioscience announced the appointment of Dr. James Garner as President. Garner brings over two decades of experience in drug development and commercialization from roles at Biogen, Takeda, and Sanofi, with a track record of overseeing 30+ product approvals. He previously served as CEO of Percheron Therapeutics and Kazia Therapeutics.